Abstract
Sorafenib, as a multi-kinase inhibitor, was the first FDA-approved anti- hepatocellular carcinoma (HCC) drug. Rhizoma Paridis saponins (RPS) as natura......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
